Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CPT1A | P50416 | 1/20 | 0.42 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312550 | 0.93 | RORC (0.46) | RORCPTGER2S1PR1PRKXIKBKE | |
| SCHEMBL13312546 | 0.91 | PTGER2 (0.48) | RORCPTGER2FFAR1FFAR4RXRA | |
| SCHEMBL13312556 | 0.90 | PTGER2 (0.48) | RORCPTGER2FFAR1FFAR4RXRA | |
| SCHEMBL13312551 | 0.88 | PTGER2 (0.47) | RORCPTGER2FFAR1FFAR4CPT1A | |
| SCHEMBL13312552 | 0.88 | PTGER2 (0.49) | RORCPTGER2FFAR1FFAR4RXRA | |
| SCHEMBL13312557 | 0.88 | PTGER2 (0.61) | RORCPTGER2FFAR1FFAR4PTGER4 | |
| SCHEMBL13312549 | 0.87 | TUBB4A (0.48) | RORCPTGER2FFAR1FFAR4RXRA | |
| SCHEMBL13312571 | 0.87 | PTGER2 (0.45) | RORCPTGER2FFAR1FFAR4RXRA | |
| SCHEMBL13312575 | 0.86 | RXRA (0.47) | RORCPTGER2FFAR1FFAR4RXRA | |
| SCHEMBL13312547 | 0.86 | PTGER2 (0.44) | RORCPTGER2FFAR1FFAR4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | RORC 451/4885PTGER2 3346/4885S1PR1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.